Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 42

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
 cash equivalents, beginning of period276,774 153,298 Cash and cash equivalents, end of period$300,484 $247,053 See accompanying condensed notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 9

PACIRA BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)  (In thousands)(Unaudited)Six Months EndedJune 30,20252024Supplemental cash flow information: Cash paid for interest$7,687 $6,988 Net cash paid for income taxes$8,233 $4,667 Non-cash investing and financing activities:  Fixed assets included in accounts payable and accrued liabilities$1,431 $604 Excise tax on share repurchases included in accrued liabilities$354 $121 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 10

PACIRA BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1—DESCRIPTION OF BUSINESS

Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) delivers innovative, non-opioid pain therapies to transform the lives of patients. The Company’s long-acting, local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. EXPAREL is currently indicated to produce postsurgical local analgesia via infiltration in patients aged six years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults for postsurgical pain management (the safety and effectiveness of EXPAREL have not been established to produce